相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer
Emmet McIntyre et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
Birgit Schoeberl et al.
CANCER RESEARCH (2010)
HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy
Marcia R. Campbell et al.
CLINICAL CANCER RESEARCH (2010)
The upgraded role of HER3 and HER4 receptors in breast cancer
Angelos K. Koutras et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2010)
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Fumin Shi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Jose Baselga et al.
NATURE REVIEWS CANCER (2009)
The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies
Anne W. Hamburger
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells
Bolin Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
Bin-Bing S. Zhou et al.
CANCER CELL (2006)
Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies
EH van der Horst et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Green fluorescent protein as a tool to study epidermal growth factor receptor function
N Hayes et al.
CANCER LETTERS (2004)
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin
CD Austin et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer
M Dunn et al.
JOURNAL OF PATHOLOGY (2004)
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
C Knuefermann et al.
ONCOGENE (2003)
The deaf and the dumb: the biology of ErbB-2 and ErbB-3
A Citri et al.
EXPERIMENTAL CELL RESEARCH (2003)